Human disease
hypereosinophilic syndrome
Mondo defines it as: “Hypereosinophilic syndrome (HES) constitutes a rare and heterogeneous group of disorders, defined as persistent and marked blood eosinophilia and/or tissue eosinophilia associated with a wide range of clinical manifestations reflecting eosinophil-induced tissue/organ damage.”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 502 | Hypereosinophilic syndrome | The group's name | 4 | Human disease |
37.5
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
Open Targets links none of these groups' human genes to this disease.
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Imatinib | None of these genes | Approved |
| Mepolizumab | None of these genes | Approved |
| Benralizumab | None of these genes | Phase 3 |
| Depemokimab | None of these genes | Phase 3 |
| Dasatinib Anhydrous | None of these genes | Phase 2 |
| Dexpramipexole | None of these genes | Phase 2 |
| Dupilumab | None of these genes | Phase 2 |
| Reslizumab | None of these genes | Phase 2 |
| Ruxolitinib | None of these genes | Phase 2 |
| Nilotinib | None of these genes | Phase 1/2 |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.